Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem ...

The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

Treatment availability and patient outcomes are critical issues for the pharmaceutical industry, particularly in eye care.

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...

MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with ...

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...

Area researchers are helping investigate the promise and the perils of psychedelic drugs as public interest grows.

Extracellular vesicles (EVs) have marked a significant shift in cancer research, introducing novel approaches for early diagnosis, targeted therapeutic delivery, and the development of personalized ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

In this article, we take a look at five biotech companies developing potentially transformative medicines to treat cystic ...

The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.

Ecstasy, also known by the pharmaceutical shorthand MDMA (an abbreviation of 3,4-methylenedioxymethamphetamine), is used illegally by millions in the U.S. The synthetic drug has been banned since ...